Clinical trial

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

NCT02681562

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-01-01

PhasePHASE2

Study timeline

Study start (unknown)2016-01-01Date precision: month

Registry last updated2016-02-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Triple Negative Breast Cancerunresolved

Interventions

olaparibDRUG · verified · RxNorm: olaparib

Sponsors & collaborators

Istituti Ospitalieri di Cremonalead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02681562 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.